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Abstract
Objective. The objectives of this study were to describe patients starting first-line biologics for JIA, to
describe characteristics over time among patients starting etanercept, and to describe patterns of second
biologic prescribing.
Methods. The British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study, and
the Biologics for Children with Rheumatic Diseases study are ongoing prospective observational cohorts,
collecting data on patients starting biologic therapy for JIA. Patients registered from 1 January 2010
starting their first biologic were compared between therapies. Patients starting etanercept before 2010
were included to analyse changes in etanercept prescribing. The pathway of patients starting a second
biologic was recorded in all patients.
Results. To 26 August 2014, 931 patients were recruited starting a first-line biologic (142 Biologics for
Children with Rheumatic Diseases; 789 British Society for Paediatric and Adolescent Rheumatology
Etanercept Cohort Study). From 2010, patients with systemic JIA (sJIA) were almost exclusively prescribed
anakinra or tocilizumab. Choice between anti-TNF therapies was largely driven by history of chronic
anterior uveitis (CAU). When investigating trends in patients starting etanercept over time, disease duration
at etanercept start, patients with sJIA, a history of CAU, and those who received concomitant oral cor-
ticosteroids decreased over time. Patients who started a second biologic from 1 January 2010 showed a
similar stratification.
Conclusion. Although etanercept remains the most common biologic prescribed for JIA, there has been a
clear shift towards the use of alternative biologics, largely driven by disease subtype and history of CAU.
This channelling of children towards specific therapies should be considered carefully in future studies and
in clinical guidelines and ongoing research.
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Rheumatology key messages
. increasingly biologics other than etanercept are being used for JIA as more become available.
. Biologic choice in JIA appears to relate to disease subtype and history of uveitis.
. Channelling towards specific therapies in JIA needs careful consideration in future comparative effectiveness
studies.
Introduction
JIA is the most common chronic rheumatic disease in
children and young people (CYP); prevalence in the UK
is 1 in 1000 [1]. CYP aged up to 16 years are diagnosed
according to the ILAR criteria [2]. In the early 2000s,
European licensing of the biologic anti-TNF etanercept
revolutionized the management of JIA in CYP with persist-
ent disease who failed to respond to or were intolerant of
the traditional non-biologic (nbDMARD) MTX [3].
Since then, a number of other biologic therapies have
been approved in Europe for JIA including abatacept,
adalimumab, canakinumab and tocilizumab, although in
the UK only etanercept and tocilizumab are formally
approved by the National Institute for Health and Care
Excellence [4, 5]. Furthermore, there is anecdotal evi-
dence that biologics licensed for use in adults with RA,
such as other anti-TNF therapies (infliximab), the IL-1 re-
ceptor antagonist anakinra and the B-inhibitor rituximab,
are also being prescribed in CYP with JIA [68].
Etanercept is often the first choice biologic in the treat-
ment of JIA. However, there may be occasions where
etanercept is not the preferred choice, for reasons of dis-
ease phenotype, effectiveness, safety or clinical context
(adherence issues, patient choice). Recent studies have
reported that IL-1 and IL-6 inhibiting drugs and IL-1 re-
ceptor antagonists, including tocilizumab, canakinumab
and anakinra, may be more effective for the treatment of
systemic JIA (sJIA) [912]. Adalimumab or infliximab may
also be the preferred treatment option for CYP with a his-
tory of chronic anterior uveitis (CAU), despite a lack of
published large head-to-head randomized controlled
trials between therapies [13, 14].
Unfortunately, it is also recognized that a proportion of
CYP will not respond to their first biologic or will experi-
ence adverse effects. There is limited evidence to support
the choice of a second or further biologic in these situ-
ations, although reports to date suggest ILAR subtype and
the availability of other biologics will influence this choice
[6]. In one study of patients who initially started etaner-
cept, the majority of patients with sJIA who switched to a
second biologic started anakinra, while those without sJIA
were more likely to choose a second anti-TNF (adali-
mumab) [15].
Factors which influence how biologics have been se-
lected in the past, both first-line and on switching, will
help inform future clinical practice, guidelines and re-
search. Therefore, the aims of this analysis are to describe
disease characteristics among CYP recently starting dif-
ferent first-line biologics for JIA; to describe changes in
patient characteristics over time among CYP starting eta-
nercept in light of an expanding evidence base for the
efficacy of other biologic therapies for JIA; and to describe
patterns of second biologic prescribing among CYP who
fail to respond to or are intolerant of their first biologic.
Methods
Study setting
This analysis used data collected in two parallel JIA
biologic registers. First, the British Society for Paediatric
and Adolescent Rheumatology Etanercept Cohort Study
(BSPAR-ETN); established in 2004, this study aims to
recruit CYP with active JIA at the point of starting etaner-
cept. Second, the Biologics for Children with Rheumatic
Diseases Study (BCRD); following recognition of the ex-
panding use of non-etanercept biologics in CYP with JIA,
in 2010, a separate national register was established to
monitor long-term safety and effectiveness of biologics
other than etanercept in CYP with JIA.
BSPAR-ETN was approved by the West Midlands
Research Ethics Committee, BCRD was approved by
the North West 7 REC Greater Manchester Central
Ethics Committee, and written informed consent from all
parents (and where appropriate patients) is provided in
accordance with the Declaration of Helsinki for both of
the studies. We did not require additional ethical approval
to analyse data in BSPAR and BCRD.
Study design
The BSPAR-ETN and BCRD are parallel studies that share
the same methodology. Designed as prospective obser-
vational cohort studies, they aim to recruit CYP at the
point of starting a biologic therapy. Recruitment to these
multicentre studies is supported by the National Institute
for Health Research Clinical Research Network in England
and respective Networks across the devolved nations
of the UK. However they do not represent all CYP in the
UK on these drugs as registration was not mandatory
(although encouraged) and it also did not include children
receiving biologic therapies within concurrent clinical
trials. The studies are not limited to first time biologic
users and both aim to recruit CYP within 6 months of
starting a biologic drug. Children can switch between stu-
dies but can be tracked through the two studies by their
unique National Health Service number.
Data collection
Baseline information is collected via questionnaires com-
pleted by the treating physician or affiliated clinical re-
search nurse. Data items include patient demographics
(age, gender), disease duration, ILAR category, current
disease activity captured using the JIA core outcome vari-
ables (active joint count, limited joint count, ESR, CRP,
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physician’s global assessment of disease, patient’s global
assessment of wellbeing, childhood health assessment
questionnaire (CHAQ)) [16], pain visual analogue scale
(VAS), history of CAU, details of current and past anti-
rheumatic therapies including any prior biologics, and all
currently prescribed medications. Follow-up data are col-
lected at 6 months, 1 year and annually thereafter.
Information on disease activity measures and changes in
drug therapy are included.
Data analysis
This analysis was divided into three main parts. First,
to compare patient characteristics between CYP starting
different first-line biologic therapies, we included all pa-
tients registered on a first biologic therapy in BSPAR-ETN
and BCRD from 1 January 2010, the date on which data
collection across all biologics commenced. Baseline char-
acteristics were described and comparisons between all
these groups were made using non-parametric descrip-
tive statistics, namely chi-squared and KruskalWallis.
Analysis was limited to drugs where at least five CYP
had started the therapy.
Second, in order to understand whether there have
been changes in patient characteristics over time among
CYP at the start of etanercept as their first-line therapy, all
patients registered on etanercept as their first biologic
therapy in BSPAR-ETN from 1 January 2003 were
included. Patients were separated into three cohorts:
recruited before 2006; recruited between 1 January
2006 and 31 December 2009; and recruited from 1
January 2010. Comparisons between these groups were
made using logistic and linear regression as appropriate.
Finally, to describe patterns of prescribing of a second
biologic in CYP who failed to respond or were intolerant of
a first biologic, all patients registered at the point of starting
either their first or second biologic therapy from 1 January
2010 in either BSPAR-ETN or BCRD were included. Among
those CYP who started a second biologic drug (either at
the point of first joining the study or after study registration),
the pattern of drugdrug switching was described in sJIA
patients, non-sJIA patients with a history of CAU, and non-
sJIA patients with no history of CAU. The reason for switch-
ing was determined from the reason listed for stopping the
preceding biologic, as recorded on the case report form
and grouped into inadequate response, adverse events,
both inadequate response and adverse events, poor adher-
ence and unknown. All analyses were performed using
Stata (StataCorp. 2013. Stata Statistical Software:
Release 13; StataCorp LP, College Station, TX, USA).
Results
Patients registered on a first biologic from
1 January 2010
From 1 January 2010 to 26 August 2014, 348 CYP were
recruited at the point of starting their first biologic therapy;
206 (59%) in BSPAR-ETN and 142 (41%) in BCRD
(Table 1). This latter study included 60 adalimumab, 30
infliximab, 35 tocilizumab and 15 anakinra patients. One
patient started rituximab and one patient had started
abatacept, and they were excluded from the analysis.
There was a difference between age and disease duration
at registration between the drug cohorts, with patients
starting etanercept at an older age (median age 12
years; P< 0.001) and patients starting adalimumab with
a longer disease duration (median 3 years; P< 0.001).
A number of differences were observed between CYP
starting different first-line biologics. The majority of chil-
dren prescribed either tocilizumab (86%) or anakinra
(100%) had sJIA compared with <5% of patients starting
one of the three anti-TNF therapies (Table 1). Anakinra and
tocilizumab were also more likely to be taken in combin-
ation with corticosteroids. Children starting anakinra were
considerably younger (median age 3 years) compared
with those starting tocilizumab (median age 8 years); how-
ever, this was not statistically significant (P = 0.308).
Patients starting anakinra were also more likely to have
a history of macrophage activation syndrome (MAS)
(P< 0.001).
There were notable differences between the three anti-
TNF therapies, with 70% of children starting adalimumab
and 73% of children starting infliximab having a history of
CAU, compared with only 5% of children starting etaner-
cept (P< 0.001). There were differences in the ILAR sub-
types across these three drugs, with a higher proportion
of children with oligoarthritis starting one of the two mono-
clonal antibodies (adalimumab or infliximab; P< 0.001),
although the oligoarthritis subgroup did not all have a his-
tory of CAU. Not unexpectedly, the median active and
limited joint counts were also lower in children starting
adalimumab or infliximab (P< 0.05). A majority of children
started their biologic drug in combination with methotrex-
ate (59% overall), although this proportion was lowest for
etanercept (46%) and highest for infliximab (87%) and
tocilizumab (89%) (P< 0.001). Twenty-nine (8%) patients
were reported to have started a biologic with no active
joints but with a history of CAU, all of whom started
adalimumab (n = 17), infliximab (n = 10) or etanercept
(n = 2).
Comparison of baseline characteristics between
patients treated with first-line etanercept over time
In total, 789 CYP were recruited starting etanercept as a
first biologic: 231 prior to 2006, 352 between 2006 and
2010, and 206 from 2010 onwards. Disease duration
reduced over time (4 years vs 3 years vs 2 years;
P< 0.001). In addition, disease activity measures
decreased over time, indicated by lower scores across
most of the JIA core outcome variables (Table 2). The
proportion of CYP starting etanercept in combination
with methotrexate reduced over time (57% vs 55% vs
46%; P = 0.029), as well as the proportion of CYP receiv-
ing concomitant oral corticosteroids (29% vs 22% vs 8%;
P< 0.001). The proportion of children starting etanercept
with either sJIA or CAU reduced over time: 16% vs 9% vs
3% (P< 0.001) and 14% vs 6% vs 5% (P< 0.001),
respectively.
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Patterns of switching from first- to second-line
biologics
From 1 January 2010, a total of 115 CYP were recruited at
the point of starting a second biologic. In addition, of the
348 CYP registered on a first-line biologic, 46 subse-
quently started a second biologic over a median of 2.2
years of follow-up, providing a total of 161 patients
switching to a second biologic. The reasons for switching
were inadequate response in 86 patients (53%), adverse
events in 32 (20%), both inadequate response and ad-
verse events in 22 (14%), issues with adherence in 9
(6%) and unknown in 12 (7%). Figures 13 show the pat-
tern of switching between first and second biologics.
Among patients with sJIA (Fig. 1) who started a second
biologic (n = 28), the majority of patients switched to toci-
lizumab (17 patients). Five patients started anakinra and
five patients started an anti-TNF therapy. Among the
seven patients whose first drug was tocilizumab, three
switched to an anti-TNF therapy and four switched to an
agent which inhibits IL-1.
Forty-five patients with a history of CAU started a
second biologic over the study period. The majority of
TABLE 1 Baseline characteristics of patients treated with a first biologic from 1 January 2010; by drug cohorts
All patients Etanercept Adalimumab Infliximab Tocilizumab Anakinra
n 346 206 60 30 35 15
Female, n (%) 224 (65) 140 (68) 40 (67) 17 (57) 16 (46) 11 (73)
Age at registration***, median (IQR), years 11 (614) 12 (814) 10 (614) 8 (511) 8 (411) 3 (213)
Disease duration***, median (IQR), years 2 (15) 2 (15) 3 (26) 2 (25) 1 (12) 0 (01)
(n = 326) (n = 193) (n = 57) (n = 28) (n = 34) (n = 14)
ILAR subtype***, n (%)
Systemic arthritis 54 (16) 7 (3) 1 (2) 1 (3) 30 (86) 15 (100)
Oligoarthritis: persistent 40 (12) 16 (8) 15 (25) 9 (30) 0 0
Oligoarthritis: extended 59 (17) 34 (17) 17 (28) 8 (27) 0 0
Polyarthritis: RF negative 102 (29) 80 (39) 10 (17) 9 (30) 3 (9) 0
Polyarthritis: RF positive 28 (8) 25 (12) 3 (5) 0 0 0
Enthesitis related arthritis 20 (6) 11 (5) 7 (12) 2 (7) 0 0
Psarthritis 20 (6) 13 (6) 6 (10) 1 (3) 0 0
Undifferentiated arthritis 8 (2) 7 (3%) 0 0 1 (3) 0
Not recorded 15 (4) 13 (6) 1 (2) 0 1 (3) 0
Concomitant MTX***, n (%) 205 (59) 95 (46) 41 (68) 26 (87) 31 (89) 12 (80)
Concomitant oral corticosteroids***,
n (%)
61 (18) 17 (8) 8 (13) 6 (20) 23 (66) 7 (47)
Ever had CAU***, n (%) 74 (21) 10 (5) 42 (70) 22 (73) 0 0
Ever had CAU, with no active joints***,
n (%)
29 (8) 2 (1) 17 (28) 10 (33) 0 0
Ever had MAS***, n (%) 11 (6) 0 1 (3) 0 5 (17) 5 (42)
(n = 191) (n = 88) (n = 38) (n = 21) (n = 30) (n = 12)
Disease activity, median (IQR)
Active joint count*** 3 (17) 4 (18) 2 (04) 2 (06) 3 (05) 5 (212)
(n = 310) (n = 187) (n = 55) (n = 27) (n = 30) (n = 11)
Limited joint count* 2 (05) 3 (16) 2 (03) 1 (06) 2 (03) 3 (013)
(n = 302) (n = 182) (n = 55) (n = 24) (n = 30) (n = 11)
Physician’s global assessment,
10 cm VAS
3 (15) 3 (15) 3 (14) 2 (14) 3 (15) 4 (26)
(n = 226) (n = 136) (n = 44) (n = 18) (n = 20) (n = 8)
Parent’s global assessment of
wellbeing, 10 cm VAS
4 (16) 4 (16) 3 (16) 3 (15) 4 (18) 5 (45)
(n = 237) (n = 143) (n = 45) (n = 17) (n = 22) (n = 10)
Childhood heath assessment
questionnaire*, 03
0.9 (0.31.5) 0.9 (0.31.5) 0.8 (0.01.4) 0.5 (0.31.0) 1.1 (0.42.0) 1.6 (1.02.1)
(n = 236) (n = 147) (n = 41) (n = 19) (n = 22) (n = 7)
Pain, 10 cm VAS 4 (17) 4 (17) 3 (17) 4 (25) 3 (16) 6 (46)
(n = 224) (n = 134) (n = 43) (n = 17) (n = 21) (n = 9)
ESR**, mm/h 10 (526) 10 (524) 7 (526) 7 (314) 24 (550) 58 (896)
(n = 282) (n = 162) (n = 50) (n = 29) (n = 31) (n = 10)
CRP***, mg/l 5 (317) 5 (311) 4 (26) 4 (15) 22 (463) 64 (2199)
(n = 271) (n = 145) (n = 50) (n = 30) (n = 34) (n = 12)
Juvenile arthritis disease activity
score, JADAS-71
12 (620) 13 (619) 10 (617) 7 (313) 17 (122) 23 (730)
(n = 175) (n = 108) (n = 33) (n = 15) (n = 13) (n = 6)
Drug cohorts with five or more patients in are represented in this table. *P<0.05. **P< 0.01. ***P<0.001. n: number of
patients with data available; IQR: interquartile range; CAU: chronic anterior uveitis; MAS: macrophage activation syndrome;
VAS, visual analogue scale.
www.rheumatology.oxfordjournals.org 1559
Biologic choices in JIA
patients either switched to or switched between adalimu-
mab and infliximab. No patient switched to etanercept
(Fig. 2).
Finally, among those patients with non-systemic JIA
and no history of CAU (n = 88), a majority switched to a
second anti-TNF therapy (n = 63) (the vast majority had
received etanercept as their first biologic), although
there were also children who switched to abatacept, toci-
lizumab, anakinra and rituximab (Fig. 3).
Discussion
This study has shown that the spectrum of biologics being
used in JIA since 2010 is wide, with five main biologics
being prescribed; etanercept, adalimumab, infliximab,
tocilizumab and anakinra. There was apparent channelling
of CYP towards different first-line therapies in association
with disease phenotype, namely ILAR category (sJIA vs
non-sJIA) and the presence of CAU. A similar pattern was
also seen in CYP switching to a second biologic.
Since 2010, a majority of children in our study starting
tocilizumab or anakinra had sJIA, which follows recent evi-
dence of efficacy of these drugs for CYP with sJIA [9, 10,
17] and data showing that etanercept may be less effect-
ive for sJIA compared with other subtypes [18]. The
median age of children starting anakinra was considerably
younger and this may reflect the different modes of deliv-
ery of these two drugs over the study period (subcutane-
ous anakinra vs intravenous tocilizumab), which may have
influenced patient or parent choice. Patients starting ana-
kinra were also more likely to have a history of MAS. MAS
is a complication of rheumatic diseases and has been
more frequently associated with sJIA [19]. Various case
reports have indicated that patients with sJIA-associated
TABLE 2 Baseline characteristics of first-line etanercept: pre-2006, from 2006 to 2010 and from 2010 onwards
Etanercept
pre-2006
Etanercept
1 January 2006 to
31/12/2009
Etanercept
1 January 2010
onwards P-values
All patients, n (%) 231 (29) 352 (45) 206 (26)
Female, n (%) 145 (63) 239 (68) 140 (68) 0.240
Age at registration, median (IQR), years 12 (914) 11 (714) 12 (814) 0.667
Disease duration, median (IQR), years 4 (27) 3 (26) 2 (15) <0.001
(n = 227) (n = 340) (n = 193)
ILAR subtype, n (%)
Systemic arthritis 37 (16) 33 (9) 7 (3)
Oligoarticular: persistent 4 (2) 11 (3) 16 (8)
Oligoarticular: extended 43 (19) 60 (17) 34 (17)
Polyarticular: RF negative 71 (31) 125 (36) 80 (39)
Polyarticular: RF positive 17 (7) 40 (11) 25 (12)
Enthesitis related arthritis 19 (8) 31 (9) 11 (5)
PsA 16 (7) 28 (8) 13 (6)
Undifferentiated arthritis 22 (10) 17 (5) 7 (3)
Not recorded 2 (1) 7 (2) 13 (6)
Concomitant MTX, n (%) 131 (57) 192 (55) 95 (46) 0.029
Concomitant oral corticosteroids, n (%) 67 (29) 79 (22) 17 (8) <0.001
Ever had chronic anterior uveitis, n (%) 33 (14) 21 (6) 10 (5) <0.001
Disease activity, median (IQR)
Active joint count 6 (312) 5 (29) 4 (18) 0.002
(n = 208) (n = 315) (n = 187)
Limited joint count 6 (311) 4 (28) 3 (16) <0.001
(n = 198) (n = 303) (n = 182)
Physician’s global assessment, 10 cm VAS 4 (36) 4 (25) 3 (15) <0.001
(n = 158) (n = 218) (n = 136)
Parent’s global assessment of wellbeing, 10 cm VAS 5 (37) 4 (27) 4 (16) 0.003
(n = 156) (n = 250) (n = 143)
Childhood heath assessment questionnaire, 03 1.4 (0.92.1) 0.9 (0.41.6) 0.9 (0.31.5) <0.001
(n = 99) (n = 199) (n = 147)
Pain, 10 cm VAS 5 (37) 4 (17) 4 (17) 0.035
(n = 133) (n = 232) (n = 134)
ESR, mm/h 20 (746) 16 (635) 10 (524) 0.001
(n = 175) (n = 284) (n = 162)
CRP, mg/l 11 (538) 7 (434) 5 (311) <0.001
(n = 178) (n = 272) (n = 145)
Juvenile arthritis disease activity score, JADAS-71 17 (1225) 15 (821) 13 (619) 0.003
(n = 104) (n = 169) (n = 108)
n: number of patients with data available; IQR: interquartile range; VAS, visual analogue scale.
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MAS have been successfully treated with anakinra [2022]
which may have influenced physician choice.
There was also marked channelling of patients with
CAU towards monoclonal antibody TNF inhibitors and
away from etanercept. This is consistent with the Dutch
national Arthritis and Biologics in Children Register, where
4% of etanercept patients and 71% of adalimumab pa-
tients had a history of CAU at baseline [23]. Infliximab has
been reported to be efficacious in the treatment of JIA-
CAU [24, 25], and to be superior to etanercept in small
studies with limited patient numbers [26, 27]. There have
also been reports that etanercept therapy is no more
beneficial than placebo in the treatment of CAU [28] and
further registry data have shown that a history of CAU was
associated with etanercept discontinuation [29]. It has
also been reported that disease activity [30] and CAU in-
flammation [31] are improved in CYP with JIA-CAU treated
with adalimumab. However, overall the evidence is very
limited in small patient numbers [32], with no account for
differences in patient characteristics between the com-
pared cohorts [33, 34]. Taken together, these data may
explain why infliximab or adalimumab was chosen over
etanercept in patients with a history of CAU. Controlled
trials investigating the best drug for JIA-CAU are ongoing
[35] and may provide more accurate evidence for the use
of certain biologics in these patients [32]. Most specific-
ally, there are currently two ongoing randomized con-
trolled trials investigating adalimumab in combination
with MTX ADUVITE and SYCAMORE trials) in the treat-
ment of JIA-CAU [13, 36].
This study has also demonstrated that since its intro-
duction, etanercept is now being prescribed earlier in dis-
ease in children with lower levels of disease activity and
severity. There has also been a reduction in the proportion
of CYP with sJIA or a history of CAU starting etanercept,
which was evident even in the years prior to 2010, sug-
gesting that a widening choice of biologics was already
affecting drug selection. This is consistent with studies in
the Dutch Arthritis and Biologics in Children register [6]
and the German Biologics JIA Registry [37], as well as in
line with recent EULAR recommendations for RA, where
earlier treatment with anti-TNF inhibitors in patients who
FIG. 1 Systemic JIA patients starting second biologic from 2010; pathway from first to second biologic, including reason
for switching
Pathway from first biologic to second biology. Numbers of first biologic patients are different from Table 1 as this figure
includes prior biologic history among those who joined the study at the point of starting a second biologic.
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have failed to reach low disease activity with nbDMARDs
is recommended [38].
In CYP switching to a second biologic, similar channel-
ling to that seen with the choice of a first biologic was also
seen. The majority of CYP with sJIA switched to tocilizu-
mab and anakinra. However, in those patients who started
tocilizumab first-line, pattern of switching was less clear,
indicating a lack of information regarding the best choice
of therapy when tocilizumab fails. The majority of patients
without sJIA but with a history of CAU switched to adali-
mumab or infliximab, with no patients switching to etaner-
cept. Patients without sJIA and with no history of CAU
tended to switch to a second anti-TNF therapy. Overall,
etanercept was less frequently seen as a second biologic,
possibly because it is the only biologic approved by
National Institute for Health and Care Excellence for first
line therapy in polyarticular JIA and therefore more com-
monly used in this position [4]. In addition, both adalimu-
mab and infliximab are commonly used anti-TNF
therapies, and despite infliximab not being licensed in
children with JIA, both are commonly used in paediatric
rheumatology practice [6]. Across all children, the most
common reason for switching was inadequate response
to their first biologic.
This analysis was completed in a large number of CYP
with JIA in paediatric rheumatology centres across the
UK. Many drug cohorts were included and contributed a
greater understanding of biologic prescribing patterns in
recent years. In addition, due to the continued availability
of etanercept patients in BSPAR-ETN from the beginning
of the 21st century, differences in patient characteristics
could be compared with more recent patients.
As with most observational studies, the data are not
without their limitations. These registers are observational
studies where registration into a biologic cohort is encour-
aged but not mandatory. Therefore, the data cannot be
used to draw conclusions about the relative proportions of
patients prescribed different biologic drugs in the UK. The
dataset is not exhaustive and therefore the data should
only be used to comment on observed patient differences.
There may be further unmeasured factors that also influ-
enced choice of therapies. As there was no qualitative
analysis of patient or physician choice, we can only
assume that these observed differences are associated
with patient and physician choice, but cannot be certain.
While the aim of both the registers was to recruit CYP with
active JIA, some patients who started first-line biologic
had no active joints, but a history of CAU. All of these
patients started either adalimumab or infliximab, with a
few starting etanercept, which therefore suggests that in
a proportion of CYP, it is their eye disease rather than their
joint disease driving the decision to start a biologic.
Many CYP with JIA are now receiving biologic therapies
in the UK. Although etanercept appears to be the most
common biologic prescribed for JIA, there has been a
clear shift towards the use of alternative biologics, includ-
ing unlicensed biologics, in certain patients, largely driven
by disease subtype (sJIA vs non-sJIA) and the presence of
CAU. This channelling of certain children towards specific
therapies will need to be considered both in terms of
FIG. 2 Non-systemic JIA patients with a history of chronic anterior uveitis starting second biologic from 2010, including
reason for switching
Pathway from first biologic to second biology. Numbers of first biologic patients are different from Table 1 as this figure
includes prior biologic history among those who joined the study at the point of starting a second biologic.
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future comparative effectiveness studies and also as a
guide to ongoing research priorities within rheumatology.
Whilst trends of patient characteristics over time have
been previously described in both an etanercept registry
and a register comparing etanercept vs adalimumab, this
is the first description of biological therapy prescribing
patterns in CYP with JIA in all of the biological therapies
currently available in the UK. As both of the UK paediatric
studies continue to develop, future analyses investigating
patient outcomes in the various drug cohorts will be pos-
sible, as well as addressing the question of the best
choice of biologic therapy as first-line use for which lim-
ited clinical experience exists.
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